Feature: artificial intelligence driving disease prevention, digital health enables personalised medicine, investment takes off
Reza Halse will be a partner at RA Capital, which held a first and final closing of its second venture fund in October.
China Merchants Group led a series C round for the antibody drug developer that was also backed by fellow corporates Tigermed and Dawn.
Boehringer Ingelheim Venture Fund returned to reinvest in the regenerative therapy developer after backing its series A round two years ago.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Synthetic biology-based vaccin developer Delonix Bioworks has completed a round co-led by Boehringer Ingelheim Venture Fund.
The Transamerica and Scor-backed patient monitoring system developer has announced it has secured $25m in its seed round.
Technology-equipped healthcare membership service Forward Health has raised $225m from investors including SoftBank Vision Fund 2 at a valuation exceeding $1bn.
Sany Group and Fosun contributed to a $61.4m round for the third-party drug development services provider, which counts Jilin Aodong Medicine as an earlier backer.
Tencent and existing investor Nan Fung Life Sciences have helped the ophthalmology drug developer complete its series B round.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
